Palvella Therapeutics (PVLA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$1.52
- Estimate
- -$1.15
- Surprise
- -32.0%
- Score today
- 5.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Palvella Therapeutics (PVLA) reported a wider loss than forecast — diluted EPS of -$1.52 against the -$1.15 estimate (a 32.0% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates PVLA Sell at 5.4/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate; this quarter's -32.0% surprise compares with a -25.3% four-quarter average. Next scheduled report: 2026-11-11.
What argues against it
- Concentration risk — Pipeline: QTORIN rapamycin
- Quality below floor (1.6 < 4.0)
- Value-trap signals (2/5): Revenue declining (-22.6% YoY), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $155.78
- Price target
- $207.48
- Stop
- $144.87
- Upside to target
- +33.2%
- Reward-to-risk
- 2.6:1
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
PVLA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.24B
- P/E (fwd)
- -20.7
- 52-week range
- $52.36–$161.38
- Off 52-week high
- 3.5%
- RSI (14)
- 53
- Volume vs avg
- 0.43×
- Score today
- 5.4/10